Page last updated: 2024-09-03
kn 04 and apyrase
kn 04 has been researched along with apyrase in 1 studies
Compound Research Comparison
| Studies (kn 04) | Trials (kn 04) | Recent Studies (post-2010) (kn 04) | Studies (apyrase) | Trials (apyrase) | Recent Studies (post-2010) (apyrase) |
|---|---|---|---|---|---|
| 12 | 0 | 0 | 1,997 | 16 | 833 |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Duncan, M; Elssner, A; Gavrilin, M; Wewers, MD | 1 |
Other Studies
1 other study(ies) available for kn 04 and apyrase
| Article | Year |
|---|---|
A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adenosine Triphosphate; Antimicrobial Cationic Peptides; Apyrase; Binding Sites; Caspase 1; Cathelicidins; Cell Membrane Permeability; Cells, Cultured; Enzyme Activation; Humans; Interleukin-1; Lipopolysaccharides; Monocytes; Protein Processing, Post-Translational; Purinergic P2 Receptor Antagonists; Receptors, Formyl Peptide; Receptors, Lipoxin; Receptors, Purinergic P2; Receptors, Purinergic P2X7 | 2004 |